Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer
Open Access
- 1 January 2020
- journal article
- research article
- Published by Elsevier BV in ESMO Open
- Vol. 5 (2), e000619
- https://doi.org/10.1136/esmoopen-2019-000619
Abstract
Background In precision medicine, somatic and germline DNA sequencing are essential to make genome-guided treatment decisions in patients with cancer. However, it can also uncover unsolicited findings (UFs) in germline DNA that could have a substantial impact on the lives of patients and their relatives. It is therefore critical to understand the preferences of patients with cancer concerning UFs derived from whole-exome (WES) or whole-genome sequencing (WGS). Methods In a quantitative multicentre study, adult patients with cancer (any stage and origin of disease) were surveyed through a digital questionnaire based on previous semi-structured interviews. Background knowledge was provided by showing two videos, introducing basic concepts of genetics and general information about different categories of UFs (actionable, non-actionable, reproductive significance, unknown significance). Results In total 1072 patients were included of whom 701 participants completed the whole questionnaire. Overall, 686 (85.1%) participants wanted to be informed about UFs in general. After introduction of four UFs categories, 113 participants (14.8%) changed their answer: 718 (94.2%) participants opted for actionable variants, 537 (72.4%) for non-actionable variants, 635 (87.0%) participants for UFs of reproductive significance and 521 (71.8%) for UFs of unknown significance. Men were more interested in receiving certain UFs than women: non-actionable: OR 3.32; 95% CI 2.05 to 5.37, reproductive significance: OR 1.97; 95% CI 1.05 to 3.67 and unknown significance: OR 2.00; 95% CI 1.25 to 3.21. In total, 244 (33%) participants conceded family members to have access to their UFs while still alive. 603 (82%) participants agreed to information being shared with relatives, after they would pass away. Conclusion Our study showed that the vast majority of patients with cancer desires to receive all UFs of genome testing, although a substantial minority does not wish to receive non-actionable findings. Incorporation of categories in informed consent procedures supports patients in making informed decisions on UFs.This publication has 34 references indexed in Scilit:
- Ethical, Legal, and Counseling Challenges Surrounding the Return of Genetic Results in OncologyJournal of Clinical Oncology, 2013
- Cancer genome-sequencing study designNature Reviews Genetics, 2013
- Managing incidental findings and research results in genomic research involving biobanks and archived data setsGenetics in Medicine, 2012
- Public preferences regarding the return of individual genetic research results: findings from a qualitative focus group studyGenetics in Medicine, 2012
- Applicability of Internationally Available Health Literacy Measures in the NetherlandsJournal of Health Communication, 2011
- Deploying whole genome sequencing in clinical practice and public health: Meeting the challenge one bin at a timeGenetics in Medicine, 2011
- Disclosure of individual genetic data to research participants: the debate reconsideredTrends in Genetics, 2011
- Hospital anxiety and depression scale cutoff scores for cancer patients in acute careBritish Journal of Cancer, 2009
- A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjectsPsychological Medicine, 1997
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993